Rationale: B cell lymphoma can co-occur with multiple myeloma (MM), and the prognosis in this case is usually poor. We propose the combination of CD19-chimeric antigen receptor (CAR) T cells and BCMA-CAR T cells for the treatment of such patients to obtain a superior prognosis. Patient concerns: We present a 50-year-old patient with previous B cell lymphoma and subsequent multiple myeloma (MM). Diagnosis: A diagnosis of B cell lymphoma and MM was made. Interventions: The patient was treated with a combination of haploidentical CD19-chimeric antigen receptor (CAR) T cells and BCMA-CAR T cells. Outcomes: After CAR T cell therapy, the monoclonal plasma cells in the bone marrow and M protein disappeared. Lessons: The combination therapy of CD19- and BCMA-CAR T cells is an effective measure to treat patients with concomitant or borderline cases of B cell lymphoma and MM.
基金：
National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81670150, 81800160]
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Hematol, Wuhan, Hubei, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Li Tongjuan,Tan Jiaqi,Chen Liting,et al.Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy[J].MEDICINE.2020,99(16):doi:10.1097/MD.0000000000019739.
APA：
Li, Tongjuan,Tan, Jiaqi,Chen, Liting,Kuang, Dong,Mao, Xia...&Zhou, Xiaoxi.(2020).Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy.MEDICINE,99,(16)
MLA：
Li, Tongjuan,et al."Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy".MEDICINE 99..16(2020)
